| Record ID | marc_records_scriblio_net/part07.dat:139422204:1140 |
| Source | Scriblio |
| Download Link | /show-records/marc_records_scriblio_net/part07.dat:139422204:1140?format=raw |
LEADER: 01140cam 2200277 4500
001 73161964 //r986
003 DLC
005 19980922114312.6
008 730615s1973 nyua b 101 0 eng
010 $a 73161964 //r986
020 $a0911216472
040 $aDLC$cDLC$dDLC
050 00 $aRC382$b.T7
082 00 $a616.8/33/061
245 00 $aTreatment of Parkinsonism:$bthe role of dopa decarboxylase inhibitors.$cEdited by Melvin D. Yahr.
260 0 $aNew York,$bRaven Press$c[1973]
300 $axiv, 303 p.$billus.$c25 cm.
440 0 $aAdvances in neurology,$vv. 2
500 $a"Contains the major presentations of a meeting held on November 28, 1972, under the joint sponsorship of the Parkinson's Disease Foundation and Merck Sharp & Dohme Research Laboratories."
504 $aBibliography: p. 279-296.
650 0 $aParkinson's disease$xCongresses.
650 0 $aAromatic amino acid decarboxylases$xInhibitors$xTherapeutic use$xCongresses.
650 0 $aEnzyme inhibitors$xCongresses.
700 10 $aYahr, Melvin D.$q(Melvin David),$d1917-$eed.
710 20 $aParkinson's Disease Foundation (U.S.)
710 20 $aMerck Sharp & Dohme.